StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil by Quarter

Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil: $101M in Q2 2026, up 21.7% from a year earlier. That is the highest of the 14 quarters on record here.

Latest, Q2 2026
101
Period ended Jun 30, 2026
Change on a year earlier
+21.7%
83 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
3
Documents cited below

Where the Q2 2026 figure comes from

“|| Delstrigo | 101 | 83 | 21 | 13 | 14 | -7 | 88 | 70 | 27”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDelstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate — HIV-1) — Worldwide sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026101+21.7%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202675+11.9%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 202579+14.5%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 202577+18.5%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 202583+38.3%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202567+19.6%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 202469+27.8%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202465+20.4%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2024Jun 30, 202460+20.0%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2024Mar 31, 202456+27.3%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 202354–Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202354–Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2023Jun 30, 202350–Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2023Mar 31, 202344–Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗

Breakdown

What makes up delstrigo (doravirine/lamivudine/tenofovir disoproxil

Cite this data

StockData. (2026). Merck Delstrigo (doravirine/lamivudine/tenofovir disoproxil ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-delstrigo

See every metric in the Merck KPI table. Data updated Oct 26, 2026.